Alzheimer's/ Memory Loss
Alzheimer’s and memory loss clinical trials are research studies that test new treatments and strategies to improve memory, thinking, and daily functioning for people with cognitive changes. They may offer eligible participants access to promising therapies, detailed evaluations, and a chance to help advance future care for those living with Alzheimer’s disease and other memory disorders.
Janssen
The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo
BMS
​The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
LAKI
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.
AACQ
This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA.
ITI-1284
This is a multicenter, randomized, double-blind, placebo-controlled, flexible-dose study of the efficacy, safety, and tolerability of ITI-1284 in patients with agitation associated with Alzheimer's dementia
ADEPT-4
The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
MapLight
This study is designed for patients ages 55 to 90 years who have been diagnosed with Alzheimer’s disease and are experiencing hallucinations and / or delusions for at least 2 months before screening visit, also known as Alzheimer’s disease Psychosis. It is a randomized, double-blind, placebo-controlled Phase 2 clinical trial evaluating the safety and effectiveness of ML-007C-MA. Study medication is administered orally. Participants are treated for approximately 7 weeks, during which the study assesses improvement in hallucinations and delusions as well as overall safety and tolerability.